DNA ploidy combined with tumor stroma as a biomarker for predicting the prognosis of stage II colorectal cancer patients and identifying candidates for chemotherapy.

Furthermore, findings from the multivariate analysis suggested that patients in the high-risk group exhibited a trend towards poorer 5-year DFS outcomes ( P = 0.056; Table 4 ), although this difference did not reach statistical significance.

also in 111,027 other papers